OssDsign is a Swedish medtech company dedicated to creating regenerative implants for improved healing of bone defects. We provide surgeons and patients around the world with an expanding range of innovative implant solutions for improved patient outcomes. OssDsign's technology is the result of collaboration between clinical researchers at the Karolinska University Hospital, Stockholm, and material science experts at the Ångström Laboratory at Uppsala University. In November 2020, OssDsign acquired Sirakoss, a Scottish company dedicated to developing the next generation nanosynthetic bonegraft substitute. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.)